THY1 and liver cancer: More importantly, the in vivo tumorigenicity assay showed that the sizes and weights of tumours originating from CD90+ liver cancer cells with suppressed Gli1 or Gli3 expression were markedly reduced compared with the negative control (Figure 4F,G).